

**CURRICULUM VITAE**  
**GEORGE PANAYOTOU**

NAME	<b>George Panayotou</b>
PRESENT APPOINTMENT	Director, Institute of Molecular Oncology, B.S.R.C. "Alexander Fleming" (2006-present)
ADDRESS	34 Fleming Street Vari 166 72 Greece
TELEPHONE	+30-210-9655054
FAX	+30-210-9653934
E-MAIL	g.panayotou@fleming.gr
DATE AND PLACE OF BIRTH	7 March 1959, Athens
NATIONALITY	Greek and British
MARITAL STATUS	Married, two sons
SECONDARY EDUCATION	Athens College (1967-1977)
HIGHER EDUCATION	University of Athens (1977-1982) Ptychion (B.Sc. equivalent) in Chemistry
POSTGRADUATE STUDIES	<ul style="list-style-type: none"> <li>• University of Sussex (1982-1983) Master of Science (M.Sc.) in Biochemistry</li> <li>• University of London and National Institute for Medical Research (1983-1987) Doctor of Philosophy (Ph.D.); Title: "Studies on the Epidermal Growth Factor Receptor"</li> </ul>
PREVIOUS APPOINTMENTS	Associate Investigator, B.S.R.C. "Al. Fleming" (1999-2006) Senior Research Fellow, Ludwig Institute for Cancer Research - University College London / Middlesex Hospital Branch (1987-1998). Honorary Lecturer, Department of Biochemistry, University College London (1997-1998)
HONOURS AND AWARDS	<ol style="list-style-type: none"> <li>1. Bodosakis Foundation (1977-1982) Scholarship for studies in Athens University</li> <li>2. Three honorary State scholarships (1977, 1979, 1980)</li> <li>3. Alexander S. Onasis Foundation (1983-1986) Scholarship for PhD studies</li> <li>4. Member of the executive committee, Hellenic Society of Biochemistry &amp; Molecular Biology (2001-2011)</li> <li>5. Associate Member of the National Council on Research and Technology (2008-2010)</li> <li>6. Member of the Administrative Board, B.S.R.C. Fleming (2006-present)</li> </ol>
JOURNALS	Member of the Editorial Board: <ul style="list-style-type: none"> <li>• Biochemical Journal</li> <li>• Journal of Proteomics</li> </ul>

## **Publications (1984 – 2011)**

**Citation Index: 7700 citations, h-index: 36**

### ***Original research papers***

1. Cellular distribution of three mammalian calcium-binding proteins related to *Torpedo* calectrin. Geisow, M.J., Childs, J., Dash, B., Harris, A., Panayotou, G., Sudhof, T. and Walker, J.H. (1984) **EMBO J.** 3, 2969-2974.
2. Reconstitution of the epidermal growth factor receptor in artificial lipid bilayers. Panayotou, G.N., Magee, A.I. and Geisow, M.J. (1985) **FEBS Lett.** 183, 321-325.
3. Transfer of reconstituted EGF receptor to receptor-negative cells by liposome fusion. Panayotou, G., Magee, A., Gregoriou, M., Rees, A. and Geisow, M.J. (1986) **Trans. Biochem. Soc.** 14, 298-299.
4. Purification and characterization of placental membrane phosphotyrosine phosphatases. Pallen, C.J., Sahlin, L., Panayotou, G. and Waterfield, M.D. (1988) **Cold Spring Harbor Symp. Quant. Biol.** 53, 447-454.
5. ADP-ribosylation is involved in the integration of foreign DNA into the mammalian cell genome. Farzaneh, F., Panayotou, G.N., Bowler, L.D., Hardas, B.D., Broom, T., Walther, C. and Shall, S. (1988) **Nucl. Acids Res.** 16, 11319-11326.
6. Purification of a phosphotyrosine phosphatase that dephosphorylates the epidermal growth factor receptor autophosphorylation sites. Pallen, C.J., Panayotou, G.N., Sahlin, L. and Waterfield, M.D. (1988) **Annals N.Y. Acad. Sci.** 551, 299-308.
7. Domains of laminin with growth factor activity. Panayotou, G., End, P., Aumaily, M., Timpl, R. and Engel, J. (1989) **Cell** 56, 93-101.
8. EGF promotes in vivo tumorigenic growth of primary chicken embryo fibroblasts expressing v-myc and enhances in vitro transformation by the v-erbA oncogene. Khazaie, K., Panayotou, G., Aguzzi, A., Samarut, J., Gazzolo, L., Jurdic, P. (1991) **Oncogene** 6, 21-28.
9. Characterization of two 85 kDa proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Otsu, M., Hiles, I., Gout, I., Fry, M.J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., Smith, A.D., Morgan, S., Courtneidge, S.A., Parker, P. and Waterfield, M.D. (1991) **Cell** 65, 91-104.
10. SH2 domains of the p85 $\alpha$  subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. McGlade, C.J., Ellis, C., Reedijk, M., Anderson, D., Mbamalu, G., Reith, A.D., Panayotou, G., End, P., Bernstein, A., Kazlauskas, A., Waterfield, M.D., Pawson, T. (1992) **Mol. Cell. Biol.** 12, 991-997.

11. Expression and characterisation of two 85 kDa components of the PI 3-kinase complex using baculovirus vectors.  
Gout, I., Dhand, R., Panayotou, G., Fry, M.J. and Waterfield, M.D. (1992) **Biochem. J.** 288, 395-405.
12. Purification and characterisation of the binding specificity of the PtdIns 3-kinase complex of bovine brain using phosphopeptide affinity columns.  
Fry, M.J., Panayotou, G., Ruiz-Larrea, F. and Waterfield, M.D. (1992) **Biochem. J.** 288, 383-393.
13. Tenascin: a modulator of cell growth.  
End, P., Panayotou, G., Entwistle, A., Waterfield, M.D. and Chiquet, M. (1992) **Eur. J. Biochem.** 209, 1041-1051.
14. Phosphatidylinositol 3-kinase: Structure and expression of the 110 kd catalytic subunit.  
Hiles, I.D., Otsu, M., Volinia, S., Fry, M.J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N.F., Hsuan, J.J., Courtneidge, S.A., Parker, P.J. and Waterfield, M.D. (1992) **Cell** 70, 419-429.
15. Structure of an SH2 domain of the p85 $\alpha$  subunit of phosphatidylinositol 3-kinase.  
Booker, G.W., Breeze, A.L., Downing, A.K., Panayotou, G., Gout, I., Waterfield, M.D. and Campbell, I.D. (1992) **Nature** 358, 684-687.
16. Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: Structural features and analysis of conformational changes.  
Panayotou, G., Bax, B., Gout, I., Federwisch, M., Wroblowski, B., Dhand, R., Fry, M.J., Blundell, T.L., Wollmer, A. and Waterfield, M.D. (1992) **EMBO J.** 11, 4261-4272.
17. Haemonectin, a granulocytic cell binding protein, is highly related to the plasma glycoprotein fetuin.  
White, H., Totty, N. and Panayotou, G. (1993) **Eur. J. Biochem.** 213, 523-528.
18. Characterisation of the bovine brain cytosolic phosphatidylinositol 3-kinase complex.  
Ruiz-Larrea, F., Vicendo, P., Yaish, P., End, P., Panayotou, G., Fry, M.J., Morgan, S.J., Thompson, A., Parker, P.J. and Waterfield, M.D. (1993) **Biochem. J.** 290, 609-616.
19. A biosensor approach to probe the structure and function of the p85 $\alpha$  subunit of the PI 3-kinase complex.  
End, P., Gout, I., Fry, M.J., Panayotou, G., Dhand, R., Yonezawa, K., Kasuga, M. and Waterfield, M.D. (1993) **J. Biol. Chem.** 268, 10066-10075.
20. A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the Hepatocyte Growth Factor / Scatter Factor receptor.  
Ponzetto, C., Bardelli, A., Maina, F., Longati, P., Panayotou, G., Dhand, R., Waterfield, M.D. and Comoglio, P.M. (1993) **Mol. Cell. Biol.** 13, 4600-4608.
21. The GTPase dynamin binds to and is activated by a subset of SH3 domains.  
Gout, I., Dhand, R., Hiles, I.D., Fry, M.J., Panayotou, G., Das, P., Truong, O., Totty, N.F., Hsuan, J., Booker, G.W., Campbell, I.D. and Waterfield, M.D. (1993) **Cell** 75, 25-36.
22. Interactions between SH2 domains and tyrosine-phosphorylated PDGF  $\beta$ -receptor sequences: Analysis of kinetic parameters using a novel biosensor-based approach.

- Panayotou, G., Gish, G., End, P., Truong, O., Gout, I., Dhand, R., Fry, M.J., Hiles, I., Pawson, T. and Waterfield, M.D. (1993) **Mol. Cell. Biol.** *13*, 3567-3576.
23. PI 3-kinase is a dual specificity kinase: Autoregulation by an intrinsic protein-serine kinase activity.  
Dhand, R., Hiles, I., Panayotou, G., Fry, M.J., Roche, S., Gout, I., Totty, N.F., Truong, O., Yonezawa, K., Kasuga, M., Courtneidge, S. and Waterfield, M.D. (1994) **EMBO J.** *13*, 522-533.
24. PI 3-kinase: Structural and functional analysis of intersubunit interactions.  
Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M.J., Yonezawa, K., Kasuga, M. and Waterfield, M.D. (1994) **EMBO J.** *13*, 511-521.
25. Phosphopeptide binding to the N-terminal SH2 domain of the p85 $\alpha$  subunit of PI 3-kinase: A heteronuclear NMR study.  
Hensmann, M., Booker, G.W., Panayotou, G., Boyd, J., Linacre, J., Waterfield, M.D. and Campbell, I.D. (1994) **Protein Science** *3*, 1020-1030.
26. A multifunctional docking site mediates signalling and transformation by the hepatocyte growth factor / scatter factor (HGF/SF) receptor family.  
Ponzetto, C., Bardelli, A., Zhen, Z., della Zonca, P., Maina, F., Giordano, S., Graziani, A., Panayotou, G. and Comoglio, P.M. (1994) **Cell** *77*, 261-271.
27. Prediction and analysis of SH2 domain - phosphopeptide interactions.  
Zvelebil, M., Panayotou, G. and Waterfield, M.D. (1995) **Protein Engineering** *8*, 527-533.
28. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein.  
Pelicci, G., Giordano, S., Zhen, Z., Salcini, A.E., Lanfrancone, L., Bardelli, A., Panayotou, G., Waterfield, M.D., Ponzetto, C., Pelicci, P.G. and Comoglio, P.M. (1995) **Oncogene** *10*, 1631-1638.
29. A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59<sup>fyn</sup>.  
Ellis, C., Kasmi, F., Ganju, P., Walls, E., Panayotou, G. and Reith, A.D. (1996) **Oncogene** *12*, 1727-1736.
30. Interactions between cytosolic components of the NADPH oxidase-p40<sup>phox</sup> interacts with both p67<sup>phox</sup> and p47<sup>phox</sup>.  
Wientjes, F.B., Panayotou, G., Reeves, E. and Segal, A.W. (1996) **Biochem. J.** *317*, 919-924.
31. Relative location of epitopes involved in synergistic antibody binding using human chorionic gonadotropin as a model.  
Klonisch, T., Delves, P., Berger, P., Panayotou, G., Laphorn, A.J., Isaacs, N.W., Wick, G., Lund, T. and Roitt, I.M. (1996) **Eur. J. Immunol.** *26*, 1897-1905.
32. Enhancement in antigen binding by a combination of synergy and antibody capture.  
Klonisch, T., Panayotou, G., Edwards, P., Jackson, A.M., Berger, P., Delves, P.J., Lund, T. and Roitt, I.M. (1996) **Immunology** *89*, 165-171.
33. Alternative modes of tyrosyl phosphopeptide binding to a Src family SH2 domain: Implications for regulation of tyrosine kinase activity.  
Ladbury, J.E., Hensmann, M., Panayotou, G. and Campbell, I.D. (1996) **Biochemistry** *35*, 11062-11069.

34. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.  
Wymann, M.P., Bulgarelli-Leva, G., Zvelebil, M.J., Pirola, L., Vanhaesebroeck, B., Waterfield, M.D. and Panayotou, G. (1996) **Mol. Cell. Biol.** *16*, 1722-1733.
35. Distinct specificity in the recognition of phosphoinositides by the Pleckstrin Homology domains of dynamin and Bruton's tyrosine kinase (Btk).  
Salim, K., Bottomley, M.J., Querfurth, E., Zvelebil, M., Gout, I., Scaife, R., Margolis, R. L., Gigg, R., Smith, C.I.E., Driscoll, P.C., Waterfield, M.D. and Panayotou, G. (1996) **EMBO J.** *15*, 6241-6250.
36. The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination.  
Spanopoulou, E., Zaitseva, F., Wang, F.-H., Santagata, S., Baltimore, D. and Panayotou, G. (1996) **Cell** *87*, 263-276.
37. Direct measurement of the substrate preference of Uracil-DNA Glycosylase.  
Panayotou, G., Brown, T., Barlow, T., Pearl, L.T. and Savva, R. (1998) **J. Biol. Chem.** *273*, 45-50.
38. Multiple interactions of PRK1 with RhoA. Functional assignment of the HR1 repeat motif.  
Flynn, P., Mellor, H., Palmer, R., Panayotou, G. and Parker, P.J. (1998) **J. Biol. Chem.** *273*, 2698-2705.
39. Solution structure of the C-terminal SH2 domain of the p85 $\alpha$  regulatory subunit of phosphoinositide 3-kinase.  
Siegal, G., Davis, B., Kristensen, S.M., Sankar, A., Linacre, J., Stein, R., Panayotou, G., Waterfield, M.D. and Driscoll, P.C. (1998) **J. Mol. Biol.** *276*, 461-478.
40. Crystal structure of a G:T/U mismatch-specific DNA glycosylase : Mismatch recognition by complementary-strand interactions.  
Barrett, T.E., Savva, R., Panayotou, G., Barlow, T., Brown, T.A., Jiricny, J. and Pearl, L.H. (1998) **Cell** *92*, 117-129.
41. Antibody recognition of epitopes on wild-type and mutant  $\beta$ -(1 $\rightarrow$ 4)-galactosyltransferase-1.  
Keusch, J., Panayotou, G., Malissard, M., Berger, E.G., Appert, H.E., Lydyard, P.M. and Delves, P.J. (1998) **Carbohydrate Res.** *313*, 37-48.
42. Binding of a diphosphotyrosine-containing peptide that mimics activated Platelet-derived Growth Factor Receptor  $\beta$  induces oligomerisation of phosphatidylinositol 3-kinase.  
Layton, M.J., Harpur, A.G., Panayotou, G., Bastiens, P.I.H. and Waterfield, M.D. (1998) **J. Biol. Chem.** *273*, 33379-33385.
43. Intermolecular interactions of the p85 $\alpha$  regulatory subunit of phosphatidylinositol 3-kinase.  
Harpur, A.G., Layton, M.J., Das, P., Bottomley, M.J., Panayotou, G., Driscoll, P.C. and Waterfield, M.D. (1999) **J. Biol. Chem.** *274*, 12323-12332.
44. Structural and biochemical evaluation of the interaction of the phosphatidylinositol 3-kinase p85 $\alpha$  SH2 domains with phosphoinositides and inositol polyphosphates.  
Lo Surdo, P., Bottomley, M.J., Arcaro, A., Siegal, G., Panayotou, G., Sankar, A., Gaffney, P.R.J.,

- Riley, A.M., Potter, B.V.L., Waterfield, M.D. and Driscoll, P.C. (1999) **J. Biol. Chem.** *274*, 15678-15685.
45. Dual specificity antibodies using a double-stranded oligonucleotide bridge.  
Chaudri, Z.N., Barlet-Jones, M., Panayotou, G., Klonisch, T., Roitt, I.M., Lund, T. and Delves, P.J. (1999) **FEBS Lett.** *450*, 23-26.
46. A read-ahead function in archaeal DNA polymerases detects pro-mutagenic template-strand uracil.  
Greagg, M.A., Fogg, M.J., Panayotou, G., Evans, S.J., Connolly, B.A. and Pearl, L.H. (1999) **Proc. Natl. Acad. Sci. USA**, *96*, 9045-9050.
47. Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity.  
Baynes, K.C., Beeton, C.A., Panayotou, G., Stein, R., Soos, M., Hansen, T., Simpson, H., O'Rahilly, S., Shepherd, P.R. and Whitehead, J.P. (2000) **Diabetologia**, *43*, 321-331.
48. The mechanism of DNA repair by uracil-DNA glycosylase: studies using nucleotide analogues.  
Rosler, A., Panayotou, G., Hornby, D.P., Barlow, T., Brown, T., Pearl, L.H., Savva, R. and Blackburn, G.M. (2000) **Nucleosides Nucleotides Nucleic Acids**, *19*, 1505-1516.
49. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit.  
Chan, T.O., Rodeck, U., Chan, A.M., Kimmelman, A.C., Rittenhouse, S.E., Panayotou, G. and Tsichlis, P.N. (2002) **Cancer Cell**, *1*, 181-191.
50. Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease.  
Zamanou, A., Samiotaki, M., Panayotou, G., Margaritis, L. and Lymberi, P. (2003) **J. Autoimmun.** *20*, 333-334.
51. Intracellularly expressed single domain antibody prevents the production of porcine retroviruses.  
Dekker, S., Toussaint, W., Panayotou, G., de Wit, T., Visser, P., Grosveld, F. and Drabek, D. (2003) **J. Virology** *77*, 12132-12139.
52. Mode of action of family 10 and 11 endoxylanases on water-unextractable arabinoxylan.  
Vardakou, M., Katapodis, P., Samiotaki, M., Kekos, D., Panayotou, G. and Christakopoulos, P. (2003) **Int. J. Biol. Macromol.** *33*, 129-34.
53. Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.  
Staikou, E.V., Routsias, J.G., Makri, A.A., Terzoglou, A., Sakarellos-Daitsiotis, M., Sakarellos, C., Panayotou, G., Moutsopoulos, H.M., Tzioufas, A.G. (2003) **Clin. Exp. Immunol.** *134*:143-50.
54. Direct interaction of MHC class II derived peptides with class Ia PI 3-kinase results in dose-dependent stimulatory effects.  
Foukas, L.C., Panayotou, G., and Shepherd, P.R. (2004) **J. Biol. Chem.** *279*, 7505-7511.
55. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system.  
Sidera, K., Samiotaki, M., Yfanti, E., Panayotou, G. and Patsavoudi, E. (2004) **J. Biol. Chem.** *279*, 45379-45388.

56. Specific interaction between S6K1 and CoA synthase: a potential link between the mTOR/S6K pathway, CoA biosynthesis and energy metabolism.  
Nemazanyy, I., Panasyuk, G., Zhyvoloup, A., Panayotou, G., Gout, I.T., Filonenko, V. (2004) **FEBS Lett.** 578, 357-362.
57. Identification of growth factor-regulated proteins using 2D electrophoresis and mass spectrometry.  
Saridaki, A. and Panayotou, G. (2005) **Growth Factors** 23, 223-232.
58. Identification of differentially expressed proteins in senescent human embryonic fibroblasts.  
Trougakos, I.P., Saridaki, A., Panayotou, G. and Gonos, E.S. (2006) **Mech. Ageing Dev.** 127, 88-92.
59. Autoantibodies against aggrecan in systemic rheumatic diseases.  
Vynios, D.H., Tsagaraki, I., Grigoreas, G.H., Samiotaki, M., Panayotou, G., Kyriakopoulou, D., Georgiou, P., Korbakis, D., Panayotou, A., Nanouri, K., Assouti, M., Andonopoulos, A.P. (2006) **Biochimie** 88, 767-773.
60. Isolation and identification of hydroxyl-platelet-activating factor from natural sources.  
Tsoupras AB, Antonopoulou S, Baltas G, Samiotaki M, Panayotou G, Kotsifaki H, Mantzavinos Z, Demopoulos CA. (2006) **Life Sci.** 79, 1796-1803.
61. Identification of MAPK Phosphorylation Sites and Their Role in the Localization and Activity of Hypoxia-inducible Factor-1 $\alpha$   
Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, Georgatsou E, Bonanou S, Simos G. (2006) **J Biol Chem.** 281, 33095-33106.
62. Generation of heavy-chain-only antibodies in mice.  
Janssens R, Dekker S, Hendriks RW, Panayotou G, van Remoortere A, San JK, Grosveld F, Drabek D. (2006) **Proc Natl Acad Sci USA.** 103, 15130-15135
63. RBM15 binds to the RNA transport element RTE and provides a direct link to the NXF1 export pathway.  
Lindtner S, Zolotukhin AS, Uranishi H, Bear J, Kulkarni V, Smulevitch S, Samiotaki M, Panayotou G, Felber BK, Pavlakis GN. (2006) **J Biol Chem.** 281, 36915-36928.
64. Biological activity of acetylated phenolic compounds.  
Fragopoulou E, Nomikos T, Karantonis HC, Apostolakis C, Pliakis E, Samiotaki M, Panayotou G, Antonopoulou S. (2007) **J Agric Food Chem.** 55, 80-89.
65. Analysis of parotid glands of primary Sjogren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets..  
Stea EA, Routsias JG, Samiotaki M, Panayotou G, Papalambros E, Moutsopoulos HM, Tzioufas AG. (2007) **Clin Exp Immunol.** 147, 81-9.
66. Characterization of Flavonoid Subgroups and Hydroxy Substitution by HPLC-MS/MS.  
Tsimogiannis, D., Samiotaki, M., Panayotou, G. and Oreopoulou, V. (2007) **Molecules** 12, 593-606.

67. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation.  
Skopeliti M, Kratzer U, Altenberend F, Panayotou G, Kalbacher H, Stevanovic S, Voelter W, Tsitsilonis OE (2007) **Proteomics** 7, 1814-24.
68. Molecular determinants of the yeast Arc1p-aminoacyl-tRNA synthetase complex assembly.  
Karanasios E, Simader H, Panayotou G, Suck D, Simos G. (2007) **J. Mol. Biol.** 374, 1077-90.
69. RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of Annexin-II.  
Maratheftis CI, Giannouli S, Spachidou MP, Panayotou G, Voulgarelis M. (2007) **Neoplasia** 9, 1012-20.
70. Bioactive polar lipids in olive oil, pomace and waste byproducts.  
Karantonis, HC, Tsantila, N., Stamatakis, G., Samiotaki, M., Panayotou, G., Antonopoulou, S. and Demopoulos, CA. (2008) **J. Food Biochem.** 32, 443-459.
71. Iron regulatory and bactericidal properties of human recombinant hepcidin expressed in *Pichia pastoris*.  
Koliaraki V, Marinou M, Samiotaki M, Panayotou G, Pantopoulos K, Mamalaki A. (2008) **Biochimie**, 90, 726-35.
72. The essential function of tim12 in vivo is ensured by the assembly interactions of its C-terminal domain.  
Lionaki E, de Marcos Lousa C, Baud C, Vougioukalaki M, Panayotou G, Tokatlidis K. (2008) **J Biol Chem.** 283,15747-53.
73. Detoxification of 2,4-dichlorophenol by the marine microalga *Tetraselmis marina*.  
Petroutsos, D., Katapodis, P., Samiotaki, M., Panayotou, G. and Kekos, D. (2008) **Phytochemistry** 69, 707-714.
74. Interaction of mitochondrial thioredoxin with glucocorticoid receptor and NF-kappaBeta modulates glucocorticoid receptor and NF-kappaB signaling in HEK 293 cells.  
Psarra AM, Hermann S, Panayotou G, Spyrou G. (2009) **Biochem J.** 422, 51-531.
75. Detection and Isolation of Antiatherogenic and Antioxidant Substances Present in Olive Mill Wastes by a Novel Filtration System.  
Stamatakis G, Tsantila N, Samiotaki M, Panayotou GN, Dimopoulos AC, Halvadakis CP, Demopoulos CA. (2009) **J Agric Food Chem** 57, 10554-10564.
76.  $\beta$ 2 glycoprotein I ( $\beta$ 2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome.  
Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. (2010) **Blood** 115, 713-723.
77. Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4.  
Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V. (2009) **Mol Cell Biochem**, 337, 299-305.
78. Differential detection of nuclear envelope autoantibodies in primary biliary cirrhosis using routine and alternative methods .

Tsangaridou E, Polioudaki H, Sfakianaki R, Samiotaki M, Tzardi M, Koulentaki M, Panayotou G, Kouroumalis E, Castanas E, Theodoropoulos PA. (2010) **BMC Gastroenterol** , 10, 28.

79. Comparative proteomic analysis of alcoholic fermentation employing a new environmental strain of *Saccharomyces cerevisiae*.  
Parapouli, M., Fragkos-Livanios, L., Samiotaki, M., Koukkou, A.I., Perisynakis, A., Hatziloukas, E., Panayotou, G. and Drainas, C. (2010) **Process Biochem.** 45, 1094-1102.
80. Compromise in mRNA processing machinery in senescent human fibroblasts: implications for a novel potential role of Phospho-ATR (ser428).  
Chandris P, Giannouli CC, Panayotou G, Kletsas D. (2010) **Biogerontology** 11:421-36.
81. Rapid magnetic heating treatment by highly charged maghemite nanoparticles on Wistar rats exocranial glioma tumors at microliter volume.  
Rabias I, Tsitrouli D, Karakosta E, Kehagias T, Diamantopoulos G, Fardis M, Stamopoulos D, Maris TG, Falaras P, Zouridakis N, Diamantis N, Panayotou G, Verganelakis DA, Drossopoulou GI, Tsilibari EC, Papavassiliou G. (2010) **Biomicrofluidics** 4, pii: 024111.
82. Analysis of Secreted Proteins for the Study of Bladder Cancer Cell Aggressiveness.  
Makridakis M, Roubelakis MG, Bitsika V, Dimuccio V, Samiotaki M, Kossida S, Panayotou G, Coleman J, Candiano G, Anagnou NP, Vlahou A. (2010) **J. Proteome Res.** 9, 3243-59.
83. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.  
Gkiafi, Z. and Panayotou, G. (2011) **J. Proteome Res.** , in press.

### ***Submitted for publication***

Interplay between oncogenic K-ras and wild-type H-ras in Caco2 cell transformation.  
Ikonomidou, G., Kostourou, V. and Panayotou, G. (2011), submitted.

Phosphorylation of the M3/6 dual-specificity phosphatase enhances the activation of JNK by arsenite.

Cotsiki, M., Oehrl, W., Samiotaki, M., Theodosiou, A. and Panayotou, G. (2011), submitted.

### ***Reviews and book chapters***

84. ADP-Ribose in DNA repair and carcinogenesis.  
Shall, S., Creissen, D., Farzaneh, F., Irwin, J., Murray, B., Panayotou, G., Tavassoli, M. and Tavassoli, M. (1984) In *Genes and Cancer* (eds. Bishop, J.M., Rowley, J.D. and Greaves, M.) pp. 175-183 (Liss, New York).
85. Structural basis for epidermal growth factor receptor function.  
Hsuan, J.J., Panayotou, G. and Waterfield, M.D. (1989) In: *Progress in Growth Factor Research* (ed. J.K. Heath), vol. 1, pp 23-32.
86. Cell surface receptors for polypeptide hormones, growth factors and neuropeptides.  
Panayotou, G. and Waterfield, M.D. (1989) **Current Opin. Cell Biol.** 1, 167-176.
87. Ligand- and antibody-affinity purification of the EGF receptor.  
Panayotou, G., Hsuan, J.J. and Waterfield, M.D. (1990) In: *Receptor Purification* (ed. G. Litwack), 1, 289-302 (Humana Press, New Jersey).

88. The structure and function of growth factor receptors and their subversion in cancer.  
Panayotou, G., Haley, J.D., Hsuan, J.J., Clark, S. and Waterfield, M.D. (1990) In: *New Concepts in Cancer: Metastasis, Oncogenes and Growth Factors* (eds. C.Etievant, J.Cros and Y.M.Rustum) pp. 166-180 (Macmillan Press, London)
89. Purification of the epidermal growth factor receptor from A431 cells.  
Panayotou, G. and Gregoriou, M. (1990) In: *Receptor Biochemistry, A Practical Approach* (ed. E. Hulme), IRL Press, Oxford/Washington DC, pp203-211.
90. Oncogenes and their relation to growth regulating receptors.  
 Fry, M.J., Panayotou, G. and Waterfield, M.D. (1992) In: *Receptor Subunits and Complexes.* (eds. Bergen, A.S.V. and Barnard, E.A.), Cambridge University Press, Chapter 15.
91. Multi-enzyme complexes associated with receptors during signal transduction.  
Panayotou, G., Fry, M.J. and Waterfield, M.D. (1992) **C.R. Acad. Sci. Paris** 314, 11-20.
92. Phosphatidylinositol 3-kinase: a key enzyme in diverse signalling processes.  
Panayotou, G. and Waterfield, M.D. (1992) **Trends Cell Biol.** 2, 358-360.
93. The assembly of signalling complexes by activated growth factor receptors.  
Panayotou, G. and Waterfield, M.D. (1993) **BioEssays** 15, 171-177.
94. Riding the evanescent wave.  
Panayotou, G., Waterfield, M.D. and End, P. (1993) **Current Biol.** 3, 913-915.
95. New insights into protein-tyrosine kinase receptor signalling complexes.  
 Fry, M.J., Panayotou, G., Booker, G.W. and Waterfield, M.D. (1993) **Protein Sci.** 2, 1785-1797.
96. Structural and functional diversity of phosphoinositide 3-kinases.  
 Zvelebil, M.J., MacDougall, L., Leever, S., Volinia, S., Vanhaesebroeck, B., Gout, I., Panayotou, G., Domin, J., Stein, R., Pages, F., Koga, H., Salim, K., Linacre, J., Das, P., Panaretou, C., Wetzker, R. and Waterfield, M.D. (1996) **Phil. Trans. R. Soc. Lond.** 351, 217-223.
97. Multiple roles for PI 3-kinases in signal transduction.  
Panayotou, G. (1996) in: *Signal Transduction*, (eds. Heldin, C.-H. and Purton, M.), Chapman and Hall, pp.189-204.
98. Growth factor signalling pathways in cancer.  
 Reith, A.D. and Panayotou, G. (1997) in : *Cellular and Molecular Biology of Cancer*, (eds. Franks and Teich), 3rd edition, Oxford University Press, pp 230-250.
99. Phosphoinositide 3-kinases: a conserved family of signal transducers.  
 Vanhaesebroeck, B., Leever, S.J., Panayotou, G. and Waterfield, M.D. (1997) **Trends Biochem. Sci.** 22, 267-272.
100. Surface Plasmon Resonance.  
Panayotou, G. (1998) in “*Encyclopedia of Immunology*” (2nd edition; eds. Delves and Roitt), Academic Press.

101. Surface Plasmon Resonance: Measuring protein interactions in real time.  
Panayotou, G. (1998) **Methods Mol. Biol.** 88, 1-10.
102. Phospholipid-binding protein domains.  
Bottomley, M.J., Salim, K. and Panayotou, G. (1998) **Biochim. Biophys. Acta** 1436, 165-183.
103. Analysis of SH2 domain - phosphopeptide interactions by Isothermal Titration Calorimetry and Surface Plasmon Resonance.  
Panayotou, G. and Ladbury, J. (2001) **Methods Mol. Biol.** 124, 295-311.
104. Molecular analysis of signal transduction pathways.  
Panayotou, G. (2004) **Autoimmun. Rev.** Suppl 1:S28-9.
105. Modulation of growth factor action by the extracellular matrix.  
Oehrl W. and Panayotou, G. (2008) **Connect Tissue Res.** 49, 145-148.
106. Proteomic methodologies and their application in colorectal cancer research.  
Ikonomou, G., Samiotaki, M. and Panayotou, G. (2009) **Crit. Rev. Clin. Lab. Sci.**, 46, 319-42.

### **Patents**

1. Polypeptides having kinase activity, their preparation and use.  
Hiles, I.D., Fry, M.J., Dhand, R., Waterfield, M.D., Parker, P.J., Otsu, M., Panayotou, G., Volinia, S. and Gout, I.: US Patent no. 5,824,492, 20 October 1998.
2. Methods to inhibit serine kinase activity and to alter intersubunit binding activity of phosphatidylinositol 3-kinase, and serine kinase active sequence of the same.  
Dhand, R., Waterfield, M.D., Hiles, I.D., Gout, I.T., Kasuga, M., Yonezawa, K., End, P., Fry, M. and Panayotou, G.: US patent no. 5,741,689, 21 April 1998.
3. Wortmannin phosphoinositide 3-kinase interaction site  
Bulgarelli-Vela, G., Wymann, M.P., Vanhaesebroeck, B., Zvelebil, Z., Panayotou, G. and Waterfield, M.D. Patent No. WO9715658, 1 May 1997.

### **Talks in international conferences**

1. "The structure and function of growth factor receptors and their subversion in cancer".  
International Symposium on New Concepts in Cancer- Metastasis, Oncogenes and Growth Factors. Castres, France, April 13-14, 1989.
2. "Growth factor receptors and cancer".  
Growth Factors: Their Nature and Role in Medicine. Berlin, Germany, September 24-28, 1989.
3. "The multi-enzyme complexes associated with growth factor receptors in signal transduction"  
Cellular Recognition and Interaction; Academie des Sciences: Paris, France, May 28-29, 1991.
4. "The analysis of receptor multienzyme complexes - biophysical approaches".  
Growth Factor Receptors in Mitogenesis and Cancer. Schloss Ringberg, Germany, July 21-25, 1991.
5. "The interaction between growth factor receptors and proteins involved in signal transduction".  
Kinases and Phosphatases. BSCB / BSDB Joint Spring Meeting. Sussex University, April 7-10, 1992.
6. "Interactions of SH2 domains with growth factor receptor autophosphorylation sites".  
European Research Conference on Molecular Regulation of Cell Proliferation - Receptors and Signal Transduction. Alpbach, Austria, June 16-19, 1992.

7. "The role of phosphatidylinositol 3-kinase in signal transduction".  
Membrane Phospholipids and Signal Transduction. Lyon, France, September 7, 1992.
8. "Kinetic analysis of SH2 and SH3 domain interactions".  
Third European BIA Symposium. London, September 23-24, 1993.
9. "Structure and function of PI 3-kinases".  
Symposium on : "Intracellular Signalling in Cell Activation". Fribourg, Switzerland, September 16, 1994.
10. "Signal transduction pathways activated by growth factor receptors".  
Fourth European BIA Symposium. Heidelberg, Germany, September 21-23, 1994.
11. "SH2, SH3 and PH domain interactions in signal transduction pathways".  
Fifth European BIA Symposium. Stockholm, Sweden, September 27-29, 1995.
12. "Interactions between signalling molecules: analysis by SPR".  
INSERM workshop: Analysis of molecular interactions using biosensor technology. Paris, France, April 22-23, 1996.
13. "Substrate specificity of DNA repair enzymes"  
Biacore Cancer Research Workshop, FEBS 2001 meeting, Lisbon, Portugal, July 2001.
14. "Analysis of protein expression, modifications and interactions"  
2<sup>nd</sup> Panhellenic Conference on Molecular Biology and Health, Athens, 5-6 October 2001.
15. "Proteomics"  
4<sup>th</sup> Panhellenic Clinical Chemistry Conference, Athens, 5 April 2002.
16. "Cancer and Proteomics".  
1<sup>st</sup> UBS Conference on Cancer, Athens, 9 April 2003.
17. "Molecular Analysis of Signal Transduction"  
Autoimmune Rheumatic Diseases Days, Athens, 24-26 June 2004.
18. "Proteomic Analysis of Growth Factor Signalling Pathways"  
1<sup>st</sup> International Conference of the Hellenic Proteomics Society, Athens, 22-25 May 2005.
19. "Proteomic Analysis of Growth Regulatory Pathways"  
4th Symposium on New Molecules in Cancer Therapeutics, Athens, 21-23 October 2005.
20. "Proteomic analysis of growth-factor signal transduction"  
28<sup>o</sup> Conference of the Hellenic Society of Biological Sciences, Ioannina, 18-20 May 2006.
21. "Proteomic approaches in cancer research"  
3<sup>rd</sup> International Biotechnology Conference, Athens, 5-7 October 2006.
22. "Signal Transduction by Growth Factor Receptors"  
FEBS Advanced Lecture Course on Matrix Pathobiology, Signaling and Molecular Targets, Patras 21-26 May 2007.
23. "Proteomics in Discovery of New Markers and Toxicity Signatures"  
45th Congress of the European Societies of Toxicology, Rhodes, 5-8 October 2008.
24. "Proteomics: New Prospects in Laboratory Medicine"  
XVI Meeting of Balkan Clinical Laboratory Federation & 7th Hellenic Congress of Clinical Chemistry, Athens 16-18 October 2008.
25. "Advanced methodologies in the study of protein interactions"  
FEBS Advanced Lecture and Practival Course on "Fundamental techniques in mammalian cell biology", Kiev, 25-31 January 2009.

26. "Proteomic approaches to study protein-protein interactions"  
Workshop on Biomolecular Interactions, Alexandroupolis, 11-14 October 2010.
27. "The role of protein domains and postranslational modifications in the formation of multienzyme signalling complexes"  
FEBS Advanced Lecture and Practival Course on "Fundamental techniques in mammalian cell biology", London, 5-12 June 2011.

Additionally:

- Seminars in various academic and research institutions in Britain and Greece.
- Participation in many international conferences.
- Member of the organizing committee of three annual conferences of the Hellenic Society of Biochemistry and Molecular Biology (2001, 2003 and 2005).
- Member of the organizing committee of the 2<sup>nd</sup> Anticancer Conference, Athens, 17-20 March 2005.
- Treasurer of the organizing committee of the FEBS/IUBMB 2008 conference.

### **Editorial and Grant Reviewing**

Member of the Editorial Advisory Panel of the Biochemical Journal (1997-2005) and member of the Editorial Board since 2005. Member of the Editorial Board of Journal of Proteomics.

Ad-hoc reviewer for the Journals: Analytical Biochemistry, Archives of Biochemistry and Biophysics, BBA, Biochemical Pharmacology, Biochemistry, Cancer Research, Current Biology, EMBO Journal, European Journal of Biochemistry, FEBS Letters, Journal of Cancer Research and Clinical Oncology, Journal of Proteome Research, Mechanisms of Ageing and Development, Mol. Cell Biol., Oncogene, PLoS ONE, Protein Science, TIBS.

Grant reviewing:

- European Commission, "Quality of Life and Management of Living Resources" Programme.
- General Secretariat of Research and Technology, Greece
- Medical Research Council, UK
- Wellcome Trust, UK
- Dutch Cancer Society
- Biotechnology and Biological Sciences Research Council, UK
- Italian Association for Cancer Research

### **Teaching experience**

1991-1998: University College London, Department of Biochemistry and Molecular Biology.

Lectures for the 'Protein Structure and Enzymology' and 'Biochemistry of Carcinogenesis' courses (3<sup>rd</sup> year undergraduates and MSc students)

Lectures on 'Oncogenes and Cell Growth' for 2<sup>nd</sup> year undergraduates.

1992-1994: University College and Middlesex School of Medicine.

3<sup>rd</sup> year intercalated B.Sc. course in Cell Pathology, lectures on 'Signal Transduction'.

1994-1998: UCL, Department of Physiology.

3<sup>rd</sup> year course in Cell Physiology, lectures and tutorials on 'Receptor Tyrosine Kinases'.

1997-1998. University of Oxford, Department of Biochemistry.

Lectures on signal transduction to 3<sup>rd</sup> year undergraduates.

Member of the BSc Board of Examiners, University College London (Biochemistry, Molecular Biology and Biotechnology).

1999-2011. University of Athens (School of Biology, School of Medicine), University of Crete (School of Medicine) and University of Thessaly (School of Medicine): Lectures to post-graduate students.

### **Grant support (1999-2011)**

Funding agency: G.S.R.T.

Title: Laboratory Network for Macromolecular Analysis by High-Technology Instrumentation

Duration: September 1999 – May 2001

Budget: 617,000 €

Funding agency: G.S.R.T.

Title: Molecular Mechanisms Regulating Senescence and Life-span

Duration: March 1999 – July 2001

Budget: 47,000 €.

Funding agency: European Commission

Title: Regulation of JNK by dephosphorylation and its role in transformation.

Duration: July 2001 – June 2003

Budget: 114,000 €.

Funding agency: European Commission

Title: Development of mass-spectroscopy based methods for protein micro-analysis.

Duration: November 2002 – October 2004

Budget: 114,000 €.

Funding agency: G.S.R.T.

Title: Matching funds for HPMF-CT-2000-00926 and MCFH-2001-00409.

Duration: July 2001 – October 2004

Budget: 75,000 €.

Funding agency: Biocryst Pharmaceuticals Inc.

Title: Purification and characterization of C1s.

Duration: March 2000 – February 2002

Budget: 120,000 €.

Funding agency: Wyeth Hellas

Title: Analysis of immunosuppressive drugs.

Duration: January 2001 – December 2010

Budget: 400,000 €.

Funding agency: G.S.R.T.

Title: Changes in gene and protein expression in human cancer cell lines over-expressing the oncoprotein HER-2/neu

Duration: March 2004 – February 2007

Budget: 50,000 €.

Funding agency: G.S.R.T.

Title: Hepcidin, a novel hormonal regulator of iron homeostasis.

Duration: March 2004 – February 2007

Budget: 19,000 €.

Funding agency: G.S.R.T.

Title: Endo-tumoral administration of novel combinations of drugs and magnetic nano-particles for the therapy and prognosis of central nervous system neoplasias.

Duration: May 2004 – April 2007

Budget: 109,000 €.

Funding agency: Association of International Cancer Research

Title: The role of the architectural factor HMGI(Y) in carcinogenesis

Duration: May 2005 – April 2008

Budget: 70,000 €.

Funding agency: European Commission

Title: Translational and Functional Onco-Genomics: from cancer-oriented genomic screenings to new diagnostic tools and improved cancer treatment (Integrated project)

Duration: May 2004 – April 2008

Budget: 93,000 €.

Funding agency: G.S.R.T.

Title: Development of services in transgenesis, disease models and macromolecular analysis in BSRC Fleming laboratories (AKMON program).

Duration: July 2005-June 2008

Budget: 150,000 €.

Funding agency: G.S.R.T.

Title: Functional Oncogenomics: Analysis of gene function for the development of novel diagnostic and therapeutic tools in colorectal cancer.

Duration: January 2007 – December 2010.

Budget: 42,000 €.

Funding agency: G.S.R.T.

Title: Role of the NF- $\kappa$ B transcription factor in carcinogenesis.

Duration: January 2007 – December 2010.

Budget: 42,000 €.

Funding agency: «Alexander S. Onassis» Foundation

Title: "Proteomic analysis of human breast cancer cell lines overexpressing HER-2"

Duration: October 2007 – September 2009

Budget: 30,000 €.

Funding agency: G.S.R.T.

Title: Mechanisms regulation the response to DNA damage in mouse oocytes.

Duration: November 2010 – October 2012.

Budget: 20,000 €

Funding agency: European Commission

Title: Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies (FP7 Integrated project)

Duration: May 2009 – April 2013

Budget: 250,000 €.